Overview

Ferumoxytol-enhanced Magnetic Resonance Imaging

Status:
TERMINATED
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
There are no current alternatives to diagnostic contrast-requiring imaging for patients with an eGFR \<30mL/min due to the association of gadolinium-based imaging modalities to nephrogenic systemic fibrosis and iodinated contrast-induced kidney injury. Ferumoxytol-enhanced imaging may offer an alternative approach.
Phase:
PHASE3
Details
Lead Sponsor:
Transmed Solutions
Treatments:
Ferrosoferric Oxide